visit us at www.thecenterformedicalhealing.com
Thursday, July 4, 2013
Remicade Biosimilars
European Agency
Favors Remicade Biosimilars Patients in some European countries with autoimmune
diseases such as rheumatoid arthritis and Crohn’s disease may soon have a
cheaper treatment option, following today’s statement from the European
Medicines Agency recommending approval of two monoclonal antibody biosimilars to
infliximab (Remicade).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment